Included in the formulation
АТХ:L.01.X.C.18 Pembolizumab
Pharmacodynamics:It binds the cytotoxic antigen PD-1 located on the surface of T-lymphocytes, monocytes and B-lymphocytes, enhancing their activity, which leads to enhanced immunological responses to tumor cells.
Pharmacokinetics:After intravenous administration, the elimination half-life is 26 days.
Elimination by the kidneys.
Indications:It is used to treat metastatic or inoperable melanoma.
II.C43-C44.C43.9 Malignant melanoma of skin, unspecified
Contraindications:Acute infectious processes, pregnancy and lactation, age under 18, individual intolerance.
Carefully:Disorders of liver function, condition after transplantation, autoimmune diseases, Crohn's disease, hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - category D. Contraindicated in pregnancy and lactation.
Dosing and Administration:Drip intravenously every 3 weeks for 2 mg / kg of weight in 100 ml of a solution of 0.9% sodium chloride or 5% dextrose for 1.5 hours. The course of treatment is 4 infusions.
The highest daily dose: 2 mg / kg.
The highest single dose: 2 mg / kg.
Side effects:Respiratory system: interstitial pneumonitis.
Hemopoietic system: hemolytic anemia.
The cardiovascular system: vasculitis, myocarditis, angiopathy.
Digestive system: pancreatitis.
Musculoskeletal system: arthritis.
Dermatological reactions: leukoclastic vasculitis, psoriasis.
Sense organs: blepharitis, iritis, conjunctivitis.
urinary system: glomerulonephritis.
Allergic reactions.
Overdose:Increased side effects.
Treatment is symptomatic.
Interaction:Clinically significant interactions are not described.
Special instructions:The drug is not compatible with other drugs.